We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 38.63 | 0 | 01:00:00 |
From Oct 2019 to Oct 2024
By Matt Grossman
GlaxoSmithKline PLC and Medicago are beginning a Phase 3 trial to test a Covid-19 vaccine that they are developing, the companies said Tuesday.
Canada-based Medicago is responsible for the vaccine to be tested in the trial, while GlaxoSmithKline developed the adjuvant. In the trial, two doses will be given 21 days apart. Up to 30,000 people will be enrolled in the placebo-controlled study.
Medicago has also begun a study to explore developing an additional vaccine candidate to address Covid-19 variants.
The decision to begin a Phase 3 trial portion follows positive interim Phase 2 results, Medicago and GlaxoSmithKline said. Full results from the Phase 2 portion will be available next month, according to the companies.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
March 16, 2021 07:43 ET (11:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
